



UNIVERSITÀ DEGLI STUDI DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in [Gynecol Endocrinol.](#) 2013 Nov;29(11):993-6. doi: 10.3109/09513590.2013.819083.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), <http://informahealthcare.com/doi/abs/10.3109/09513590.2013.819083>

Is Letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?

Revelli A.¹ MD PhD

Porcu E.², MD

Levi Setti P.E.³, MD

Delle Piane L.^{1,3}, MD

Merlo D.F.⁴, PhD

and Anserini P.⁵, MD

¹Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Torino, Italy

²Infertility and ART Center, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

³Department of Gynecology, Division of Gynecology and Reproductive Medicine, IRCCS Istituto Clinico Humanitas, University of Milan, School of Medicine, Rozzano (MI), Italy

⁴Epidemiology, Biostatistics and Clinical Trials IRCCS, AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Centre for Reproductive Medicine IRCCS, AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Corresponding author

Paola Anserini, MD

Centre for Reproductive Medicine IRCCS, AOU San Martino-IST Istituto Nazionale
per la Ricerca sul Cancro, Genova, Italy

Ph: 0039-010-5555842

paola.anserini@fastwebnet.it

Short title (Running Head) : Le+Gn vs.Gn-only in BC

Keywords

Letrozole; gonadotropins; fertility preservation; breast cancer; oocyte cryostorage

Summary

Objective: To assess the advantages and disadvantages of using Letrozole for controlled ovarian stimulation (COH) in young patients with estrogen receptor-positive (ER+) breast cancer, wishing to cryopreserve oocytes.

Design: Retrospective cohort analysis.

Setting: Sixteen Italian Units for Reproductive Medicine and In Vitro Fertilization.

Methods: Data of 50 ER+ breast cancer patients undergoing COH to cryopreserve oocytes before gonadotoxic chemotherapy with a Letrozole plus gonadotropins (Le+Gn) protocol were compared with those of 25 young women with ER- breast cancer, submitted to COH using a protocol with gonadotropins alone (Gn-only).

Results: The Le+Gn protocol implied a significantly lower total Gn consumption and allowed to maintain significantly lower circulating E2 levels at all checkpoints throughout stimulation (peak E2 value 446 ± 357 vs. 1553 ± 908 pg/ml, respectively; $p=0.001$). On the other side, the Le+Gn protocol allowed a significantly lower yield of oocytes available for cryostorage (6.6 ± 3.5 vs. 8 ± 5 , respectively; $p=0.038$).

Conclusions: In breast cancer patients, the association of Letrozole to Gn significantly reduces the number of oocytes available for cryostorage in comparison with the use of Gn alone. On the other side, it is associated with significantly lower E2 levels during the whole stimulation cycle, a safety issue that has been traditionally considered advantageous in case of ER+ cancers.

Introduction

Fertility preservation is an important issue for young women affected by cancer, Among malignancies that affect women in the fertile age, breast cancer is one of the most frequent; more and more frequently these patients ask to be submitted to controlled hormonal ovarian stimulation (COH) in order to retrieve and cryostore oocytes (1-3).

The available laboratory techniques to freeze and store human oocytes have reached a high effectiveness in maintaining oocyte viability and competence, However the number of eggs that are cryostored is still a critical issue in determining the chance of having a baby after cancer especially when the slow freezing technique is applied (4) . On the other side, when the patient is affected by an estrogen-receptor positive (ER+) cancer, COH cannot be aimed exclusively at retrieving the highest number of eggs, but must even expose to the lowest possible levels of estrogens (5).

Due to its property of keeping low estradiol (E2) levels during COH, the aromatase inhibitor Letrozole has been proposed in association to Gn for oocyte harvesting in patients with E2-sensitive malignancies (6-8,11) cancer. The effectiveness of Letrozole for COH has been evaluated mainly in non-oncological patients with polycystic ovary (PCO) (12, 13), but only a few reports have studied its effectiveness in women with normal ovaries (14-16).

Our study is the first to evaluate the association Letrozole-plus-Gn (Le+Gn protocol) in comparison with the classical COH with Gn alone (Gn-only protocol) in an homogeneous cohort of young women, all affected by breast cancer. We conducted a multicenter retrospective analysis specifically focusing on two objectives: a) the protocol effectiveness in terms of oocyte retrieval and availability of eggs for cryopreservation, and b) the circulating E2 levels during COH.

Materials and Methods

Patients

Among Italian in vitro fertilization (IVF) Units that routinely use oocyte freezing for IVF patients, sixteen accepted to participate; they cryopreserved oocytes in breast cancer patients during the time period December 2000 - January 2012.

Overall, a total number of 75 young women affected by breast cancer (1-19 per IVF Unit) were included in the study; each patient was submitted to a single cycle of COH aimed at obtaining oocytes for fertility preservation. The patients' basal characteristics are shown in Table 1.

Table 1. Patients' clinical characteristics. Data are expressed as mean±SD.

	<u>Le-Gn</u>	<u>Gn-only</u>	<u>P</u>
	<u>(n=50)</u>	<u>(n=25)</u>	
<u>Age (years)</u>	<u>34.4 ± 5.2</u>	<u>35.1 ± 4.9</u>	<u>ns</u>
<u>Patients aged ≥ 38 yrs (%)</u>	<u>26</u>	<u>36</u>	<u>ns</u>
<u>Patients with children (%)</u>	<u>7.5</u>	<u>5.2</u>	<u>ns</u>
<u>Patients with previous infertility (%)</u>	<u>5.8</u>	<u>11.5</u>	<u>ns</u>
<u>Patients with previous ovarian surgery (%)</u>	<u>6.8</u>	<u>8.6</u>	<u>ns</u>
<u>Smokers (%)</u>	<u>19</u>	<u>5.2</u>	<u>ns</u>
<u>BMI</u>	<u>21.8 ± 3</u>	<u>20 ± 1.9</u>	<u>ns</u>
<u>Basal FSH (IU/L)</u>	<u>7.3 ± 2.7</u>	<u>7.8 ± 3</u>	<u>ns</u>
<u>AMH (ng/ml)</u>	<u>3.9 ± 2.6</u>	<u>4.1 ± 3</u>	<u>ns</u>
<u>Antral Follicle Count (AFC)</u>	<u>10 ± 5.5</u>	<u>12 ± 9.9</u>	<u>ns</u>

When the breast cancer was ER+ (50 patients), Letrozole was added to Gn, and the Le+Gn protocol was used; on the contrary, when the cancer was ER- (25 patients),

only gonadotropins (Gn-only protocol) were administered. The latter patients were used as a control group to assess the effects of Letrozole on COH.

Ovarian stimulation regimens

The ovarian Le+Gn stimulation (50 COH cycles) was accomplished with an antagonist protocol as described by Oktay starting always in the early follicular phase(8-9) The Gn-only stimulation regimen (25 cycles) was performed administering subcutaneous Gn (recombinant FSH or hMG) from cycle day 2 with an antagonist protocol or with a long GnRH agonists protocol. The Gn starting dose was chosen for each patient on the basis of the following clinical characteristics: age, body mass index, basal (day 3) FSH level, anti-mullerian hormone level, antral follicle count, and was then adjusted according to ovarian response. Recombinant FSH (rec-FSH; Gonal F, Merck-Serono, Geneva, Switzerland, or Puregon, MSD, Whitehouse Station, NJ, USA) was used in most stimulation cycles (82% in the Le+Gn group and 92% in the Gn-only group, respectively), whereas human menopausal gonadotropins (hMG; Ferring, Darmstadt, Germany) was used in 18% of cycles in the Le+Gn group and in 8% of cycles in the Gn-only group.

Ovarian stimulation was monitored by serial transvaginal ultrasound (US) examinations coupled to serum E2 measurements starting on stimulation day 5-8. When appropriate according to ovarian US and E2 levels, 10,000 IU of hCG (Gonasi HP, IBSA, Lugano, Switzerland) were administered and oocyte pick-up (OPU) was performed 35-37 hours later under US guidance. The retrieved oocytes were immediately observed to assess nuclear maturity, and metaphase II eggs were cryostored; the slow-freezing or the vitrification techniques (17) were used in 70% and 30% of cases, respectively.

End points and statistics

The primary end-points of the present study were: a) the number of mature, cryopreservable oocytes, and b) E2 levels during stimulation. Secondary end-points were the following: proportion of cancelled cycles, total amount of administered Gn, stimulation length, E2/retrieved and E2/cryopreserved oocyte ratios.

The Chi square test statistics was used to compare categorical covariates, and continuity correction was used to account for small expected observations. The mean levels of the studied covariates was tested by means of the Student *t* test or the Welch test according to the results of Levene's test for equality of variance. Differences were considered statistically significant at an α level <0.05 .

Results

The two groups of patients did not significantly differ for any of the basal clinical characteristics (Table 1).

Overall, four cycles out of 75 were cancelled before OPU, one in the Le+Gn group and three in the Gn-only group; however, only one cycle in the Gn-only group was cancelled for inadequate ovarian response (Table 2), whereas the others were stopped for sudden health problems that forced to anticipate the oncological treatment, unrelated to the stimulation itself.

The starting Gn dose and the total dose of administered Gn were significantly lower in the Le+Gn than in the Gn-only group (Table 2). The number of developing follicles was similar with both protocols, but the number of oocytes retrieved was borderline significant in favor of Gn-only regimen and the number of mature oocytes available for cryopreservation (6.6 ± 3.5 vs. 8 ± 5 ; $p=0.038$) was significantly higher in the Gn-only group (Table 2).

The anti-estrogenic effect of Letrozole resulted in significantly lower E2 levels at all checkpoints during stimulation (Figure 1). The peak E2 level the day of hCG administration (D-hCG) was approximately one third in the Le+Gn group than in the Gn-only group (Table 2).

Discussion

The property of stimulating follicular recruitment and growth while keeping low E2 levels renders Letrozole particularly interesting for young women with E2-sensitive malignancies (e.g., endometrial and ER+ breast cancers) wishing to preserve their fertility by COH followed by oocyte or, whenever legal, embryo cryostorage (6-11, 18). On the other side the number of oocytes available for freezing is a key issue in determining the chances to preserve fertility especially with the slow –freezing technique, which was applied in the majority of cases in this study. Oktay (18) reported a better oocytes recovery with the Le+Gn protocol compared with Tamoxifen-alone and Tamoxifen-plus-Gn in breast cancer patients. However a lower number of retrieved oocytes was observed in Le+Gn-stimulated breast cancer patients compared with Gn-only-stimulated healthy controls (8), and in Le+Gn-stimulated breast cancer patients compared with women with hormonal-independent cancers stimulated by Gn alone (19).

Our study is the first in which the Le+Gn stimulation regimen is compared with a Gn-only COH regimen in an homogeneous group of young women affected by breast cancer, among which the ER- subjects, stimulated by Gn-only, represent the control group.

The technical experience with oocyte freezing in Italy is one of the widest in the world (20-24) and oocyte freezing is frequently offered to oncological patients. We observed that the number of mature and oocytes, was significantly (about 40%) lower when Letrozole was used (Table 2). Although an early timing of hCG administration

as been held responsible for the higher percentage of immature oocytes in letrozole stimulation (8), in this study also the overall number of retrieved oocytes was lower in patients than in controls stimulated without Letrozole. Indeed the number of oocytes obtained in our study by the Le+Gn regimen was lower than previously published (8, 19), suggesting a more cautious attitude for COH in Italy and/or a higher proportion of poorly-responding women among Italian patients. It must be remarked, in fact, that about one third of the patients included in our survey was older than 38 at the time of stimulation. the different proportion of smokers in Le-Gn and Gn-only groups and the different number of cycles receiving HMG instead of recFSH may have contributed to a lower ovarian response acting as confounders on the role of letrozole.”

Above all a possible reason why in our study the oocyte yield was lower when Letrozole was used is that both the Gn starting and the Gn total doses were significantly lower in the Le+Gn group than in the Gn-only group (Table 2). Anyway, it was reported that increasing the Gn dose associated with Letrozole is not effective in enhancing oocyte yield (25); thus, the lower dose of Gn should not be responsible for the reduced oocyte yield. Alternatively, instead, it could be due to a lower ovarian responsiveness of patients with ER+ cancers in comparison to women with E2-insensitive tumors, that was reported by some (26), but not by others (27).

The number of oocytes available for freezing is indeed very important, but dealing with E2-sensitive cancers, the patient's exposure to E2 is another major issue. Estrogens are known to actively stimulate the proliferation of ER+ breast cancer cells (28,29). Until the recent past, ovarian stimulation for fertility sparing was forbidden for women with E2-sensitive cancers because of the fear of the stimulating effect of E2 on cancer progression. Indeed Letrozole-including protocols have been proposed for cancer patients just with the scope of overcoming this limitation and have been associated with a comparable cancer recurrence rate to that observed for breast

cancer patients who were not willing to cryopreserve and did not undergo ovarian stimulation (7).

Our study clearly shows that the use of the Le+Gn protocol implies a significantly lower E2 levels from the first checkpoint (day 5-8 of the stimulation cycle), throughout the whole stimulation cycle, until the day in which hCG was administered (D-hCG; Figure 1).

Moreover, we observed a significantly lower E2/oocyte ratio with the Le+Gn regimen, witnessing the lower E2 amount produced by each single developing follicle (Table 2). The observed reduction in circulating E2 in women who received Letrozole was very relevant - approximately 70% - compared to E2 levels observed in patients receiving Gn-only. Is the fear of worsening the prognosis of ER+ breast cancer patients performing a "classical" COH with Gn-only justified? Indeed it appears to be based on rather uncertain scientific data for at least two reasons: (a) it is unknown to which extent a short (some days) exposure to high E2 levels can affect the global prognosis of a woman with an ER+ breast cancer (5), and (b) it is unknown which concentration of E2 is needed to significantly accelerate ER+ breast cancer cells proliferation. On one side Letrozole administration seems reasonable in order to expose ER+ breast cancer patients to the lowest E2 levels possible, on the other side it appears questionable. Is it correct (and ethical) to apply a COH protocol that is known to have a lower chance to preserve fertility (significantly less cryopreservable oocytes) to avoid a possible risk of harmful effects of elevated circulating E2 levels? These effects have not been precisely quantified and could also be elicited by much lower E2 levels, e.g. those reached during Le+Gn COH.

With the limits of its retrospective and multicentre nature, the present study shows that in breast cancer patients the Le+Gn stimulation protocol implies a lower availability of cryopreservable oocytes than the classical Gn-only regimen, and

implies a significantly lower E2 exposure. Our observations do not allow to assess if the Le+Gn protocol is the best available option for ER+ breast cancer patients, a satisfactory compromise between safety and effectiveness. Further studies aimed at precisely assessing the impact of a short and limited E2 exposure on the kinetics of breast cancer cells and on the prognosis of premenopausal ER+ breast cancer will help to give a definite answer to this issue.

Acknowledgments

The Authors thanks all Italian Reproductive Units that have contributed to this study by sending their data: Dipartimento Materno-Infantile, Istituto di Ostetricia e Ginecologia Università di Modena e Reggio Emilia, Modena; Centro Sterilità Policlinico Mangiagalli Regina Elena, Milano; Centro di Medicina della Riproduzione Biogenesi, Monza; Tecnobios Procreazione, Bologna; Centro di Fisiopatologia della Riproduzione Ospedale di Lugo di Romagna, Lugo di Romagna; Centro Fisiopatologia della Riproduzione, Ginecologia e Ostetricia, Bari; Centro di PMA, Università di Padova, Padova; Centro GENERA, Roma; Dipartimento di Scienze Ostetriche e Ginecologiche, Medicina della Riproduzione, Università degli Studi di Napoli Federico II, Napoli; Centro di Fisiopatologia della Riproduzione, IRCCS San Raffaele, Milano; Centro PMA, Ospedale Luigi Sacco, Milano; Azienda Ospedaliera San Giuseppe Moscati, Avellino.

Declaration of interest

The authors report no declarations of interest.

References

1. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53:753-62.
2. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11:422-34

3. Revelli A, Molinari E, Salvagno F, Delle Piane L, Dolfin E, Ochetti S. Oocyte cryostorage to preserve fertility in oncological patients. *Obstet Gynecol Int.* 2012;2012:525896.
4. Boldt J. Current results with slow freezing and vitrification of the human oocyte. *Reprod Biomed Online.* 2011;23:314-22.
5. ISFP Practice Committee, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, Nagy P, Falcone T, Andersen C, Hovatta O, Wallace H, Meirou D, Gook D, Kim SH, Tzeng CR, Suzuki S, Ishizuka B, Dolmans MM. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. *J Assist Reprod Genet.* 2012;29:465-8.
6. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. *Fertil Steril.* 2007;88:657-64.
7. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. *J Clin Oncol.* 2008;26:2630-5.
8. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. *J Clin Endocrinol Metab.* 2006; 91:3885-90.
9. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *J Clin Oncol.* 2005;23:4347-53.
10. Oktay K :Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro

fertilization to cryopreserve their embryos for fertility preservation. *J Clin Oncol* 2005;23:3858-9.

11. Ben-Haroush A, Farhi J, Ben-Aharon I, Sapir O, Pinkas H, Fisch B. High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols. *Isr Med Assoc J*. 2011;13:753-6.
12. Badawy A, Abdel Aal I, Abulatta M. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. *Fertil Steril*. 2009;92:849-52.
13. Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. *Fertil Steril* 2009;92:236-9.
14. Verpoest WM, Kolibianakis E, Papanikolaou E, Smitz J, Van Steirteghem A, Devroey P. Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. *Reprod Biomed Online*. 2006;13:166-72
15. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B. Aromatase inhibitors in stimulated IVF cycles. *Reprod Biol Endocrinol*. 2011;9:85.
16. Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, Tur R, Callejo J, Checa MA, Farré M, Espinós JJ, Fábregues F, Graña-Barcia M; Reproductive Endocrinology Interest Group of Spanish Society of Fertility. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. *Hum Reprod Update*. 2008;14:571-82.

17. Edgar DH, Gook DA. A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. *Hum Reprod Update*. 2012;18:536-54.
18. Oktay K, Buyuk E, Akar Z, Rosenwaks N, Libertella N: Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *Fertil Steril* 2004; 82: s1.
19. Checa Vizcaíno MA, Corchado AR, Sastre I Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. *Reprod Biomed Online* 2012;24:606-10.
20. Levi Setti PE, Albani E, Novara PV, Cesana A, Morreale G. Cryopreservation of supernumerary oocytes in IVF/ICSI cycles. *Hum Reprod*. 2006;21:370-5.
21. Borini A, Levi Setti PE, Anserini P, De Luca R, De Santis L, Porcu E, La Sala GB, Ferraretti A, Bartolotti T, Coticchio G, Scaravelli G. Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome. *Fertil Steril* 2010;94:1662-8.
22. Porcu E, Fabbri R, Damiano G, Fratto R, Giunchi S, Venturoli S. Oocyte cryopreservation in oncological patients. *Eur J Obstet Gynecol Reprod Biol*. 2004;113 Suppl 1:S14-6.
23. Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, Moscarini M, Ambrosini G. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. *Reprod BioMed Online* 2008;17:265-267.
24. Porcu E, Ciotti MP, Venturoli S. *Handbook of human oocyte cryopreservation*. Cambridge University Press, 2012

25. Lee S, Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? *Fertil Steril*. 2012;98:961-4.
26. Domingo J, Guillén V, Ayllón Y, Martínez M, Muñoz E, Pellicer A, Garcia-Velasco JA. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. *Fertil Steril* 2012;97:930-934.
27. Almog B, Azem F, Gordon D, Pauzner D, Amit A, Barkan G, Levin I. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. *Fertil Steril*. 2012;98:957-60.
28. Germain D. Estrogen carcinogenesis in breast cancer. *Endocrinol Metab Clin North Am* 2011;40:473-84.
29. Chang M. Dual roles of estrogen metabolism in mammary carcinogenesis. *BMB Rep* 2011;44:423-34.